All relevant facts, the FDA do have the final say, but items such as Japan introducing new laws to FastTrack regenerative medicine in 2016 (not hyperhidrosis medicines), and the fact that the FDA did want an adult study conducted but MSB chose to not go that route, played big into the final result. Yes, MSB's drug was fast-tracked, but that means nothing if the data isn't up to convincing the FDA. And whilst a submission itself is accepted as 'complete', the fast tracking here meant MSB didn't get a mid-cycle review (as their review process only took 6 months). BOT on the other hand had a mid-cycle review where no issues were flagged. Yes the FDA said all good about MSB's manufacturing, but that doesn't seem to be the clincher here in rejecting the drug for the lack of data's sake. But anyway, again, the FDA always hold the final say. I do hope this is one of the main reasons we still haven't gone for a larger run - parties concerned that FDA approval may not occur. Hopefully we can expect to see even greater SP increases after FDA approval next month.
- Forums
- ASX - By Stock
- Ann: Appointment of Dr Howie McKibbon as CEO
All relevant facts, the FDA do have the final say, but items...
-
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $654.2M |
Open | High | Low | Value | Volume |
37.0¢ | 37.0¢ | 34.5¢ | $2.959M | 8.301M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 74186 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 422090 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 74186 | 0.360 |
4 | 462590 | 0.355 |
12 | 1051622 | 0.350 |
14 | 497784 | 0.345 |
12 | 218070 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 422090 | 8 |
0.370 | 527474 | 6 |
0.375 | 459885 | 7 |
0.380 | 245528 | 8 |
0.385 | 653019 | 10 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online